Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Keith B. Gorden"'
Autor:
Anissa S. H. Chan, Takashi O. Kangas, Xiaohong Qiu, Mark T. Uhlik, Ross B. Fulton, Nadine R. Ottoson, Keith B. Gorden, Yumi Yokoyama, Michael E. Danielson, Trinda M. Jevne, Kyle S. Michel, Jeremy R. Graff, Nandita Bose
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Imprime PGG (Imprime) is in late-stage clinical development as a combinatorial agent with several therapeutic modalities. Here we present pre-clinical mechanistic data supportive of Imprime, a soluble yeast β-1,3/1,6-glucan pathogen-associated molec
Externí odkaz:
https://doaj.org/article/3ecab3a75dcc4fa29265f88741647ad9
Autor:
Anissa S H Chan, Adria Bykowski Jonas, Xiaohong Qiu, Nadine R Ottoson, Richard M Walsh, Keith B Gorden, Ben Harrison, Peter J Maimonis, Steven M Leonardo, Kathleen E Ertelt, Michael E Danielson, Kyle S Michel, Mariana Nelson, Jeremy R Graff, Myra L Patchen, Nandita Bose
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0165909 (2016)
Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic antibodies. Mechanistically, Imprime acts as pathogen-associated molecu
Externí odkaz:
https://doaj.org/article/357100ff914f42d797e55b32fe9e7a5d
Autor:
Ben J. Harrison, Peter J Hurley, Nadine Ottoson, Michele Gargano, Blaine Rathmann, Xiaohong Qiu, Nandita Bose, Arkadiusz Z. Dudek, Gautam Jha, Keith B. Gorden
Publikováno v:
Anticancer Research. 40:1467-1473
Background BTH1677 is a beta-glucan pathogen-associated molecular pattern (PAMP) being evaluated as a novel immunotherapy of cancer. We previously described that the presence of antibodies against beta-glucan (ABA) in serum is necessary for BTH1677 a
Autor:
Steven M. Leonardo, Ross B. Fulton, Kathryn A. Fraser, Mark T. Uhlik, Xiaohong Qiu, Jamie Lowe, Mark A. Matson, Keith B. Gorden, Lindsay R Jordan, Nadine R. Ottoson, Nandita Bose, Blaine Rathmann, Adria Jonas, Richard Walsh, Takashi O Kangas, Ben Harrison, Anissa S.H. Chan, Kathleen E. Ertelt, Jeremy R. Graff, Richard D. Huhn
Publikováno v:
The Journal of Immunology. 202:2945-2956
Imprime PGG (Imprime) is an i.v. administered, yeast β-1,3/1,6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (AB
Autor:
Mark T. Uhlik, Keith B. Gorden, Christina Preece, Jeremy R. Graff, Ben Harrison, Alison Stopeck, Patricia A. Thompson
Publikováno v:
Cancer Research. 79:P5-12
Purpose: Recent observations suggest a positive association between the presence of tumor-associated myeloid and lymphoid immune cells and clinical responses to HER2 therapies. The specific immune cell composition of HER2+ tumors and the effects of t
Autor:
Nandita eBose, Anissa SH eChan, Faimola eGuerrero, Carolyn M Maristany, Richard M Walsh, Katie E Ertelt, Adria Bykowski Jonas, Keith B Gorden, Christine M Dudney, Lindsay R Wurst, Mike E Danielson, Natalie eElmasry, Andrew S Magee, Myra L Patchen, Xiaohong eQiu, John P Vasilakos
Publikováno v:
Frontiers in Immunology, Vol 4 (2013)
The immunomodulatory properties of yeast β-1,3/1,6 glucans are mediated through their ability to be recognized by human innate immune cells. While several studies have investigated binding of opsonized and unopsonized particulate β-glucans to human
Externí odkaz:
https://doaj.org/article/b7ce282968f54f0b9afc6646f7803a14
Autor:
J. R. Trout, Myra L. Patchen, P. Sadjadian, Folker Schneller, Nandita Bose, P. Mattson, M. Gargano, Jens Kollmeier, Jamie Lowe, M. Beliveau, Richard Walsh, J. F. Marier, Michael Thomas, Keith B. Gorden
Publikováno v:
Investigational New Drugs
SummaryIntroduction BTH1677, a 1,3–1,6 beta-glucan immunomodulator, stimulates a coordinated anti-cancer immune response in combination with anti-tumor antibody therapies. This phase II study explored the efficacy, pharmacokinetics (PK), and safety
Autor:
Ben J. Harrison, Nandita Bose, Xiaohong Qiu, Kyle S. Michel, Jeremy R. Graff, Richard Walsh, Mariana I. Nelson, Nadine R. Ottoson, Adria Jonas, Keith B. Gorden, Steven M. Leonardo, Michael E. Danielson, Kathleen E. Ertelt, Peter Maimonis, Anissa S.H. Chan, Myra L. Patchen
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 11, p e0165909 (2016)
PLoS ONE, Vol 11, Iss 11, p e0165909 (2016)
Imprime PGG (Imprime), an intravenously-administered, soluble β-glucan, has shown compelling efficacy in multiple phase 2 clinical trials with tumor targeting or anti-angiogenic antibodies. Mechanistically, Imprime acts as pathogen-associated molecu
Autor:
Mark T. Uhlik, Michael E. Danielson, Nadine R. Ottoson, Nandita Bose, Jamie Lowe, Jeremy R. Graff, Richard D. Huhn, Ben Harrison, Xiaohong Qiu, Steven M. Leonardo, Jose Iglesias, Myra L. Patchen, Anissa S.H. Chan, Kyle S. Michel, M. Ma, Keith B. Gorden, Richard Walsh, Katie Ertelt, A. Bykowski Jonas
Publikováno v:
European Journal of Cancer. 69:S106-S107
Autor:
Ben J. Harrison, Keith B. Gorden, Jamie Lowe, Steven M. Leonardo, Richard Walsh, Mark Uhlik, Michael Chisamore, Kathleen E. Ertelt, Nandita Bose, Michele Gargano, Jeremy R. Graff, Bruno Osterwalder
Publikováno v:
Cancer Research. 78:LB-129
Imprime PGG is a novel, IV administered 1,3/1,6 β-glucan PAMP (pathogen-associated molecular pattern) that activates innate immune effector cells to enhance tumor killing, to repolarize the suppressive myeloid cells of the tumor microenvironment and